Feed SCYX
SC

SCYNEXIS, Inc.

SCYX · NASDAQ

$4.46 -0.67% (-$0.03)
1M -15.21%
Market Cap $28.0M
P/E Ratio -
Div. Yield -
ROE 21.10%
Piotroski F-Score Weak
2/9
Valuation
96 /100
Cheap
P/B 0.42x
P/S 1.46x
EV/FFO N/A
Growth
100 /100
Growing
Book val. growth 148.11%
Rev. growth 59.35%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 53.27%
Op. margin 117.61%
FCF margin 69.26%
Quality
3 /100
Poor
ROE 21.10%
ROA 13.65%
Asset turnover 0.26x
Debt
100 /100
Low
Current ratio 9.65x
Debt/Equity 0.03x
Net debt/EBITDA N/A
Stability
19 /100
Unstable
Rev. volatility 1,455.71%
EPS volatility 164.02%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SCYX
Online

About the company

SCYNEXIS, Inc. (SCYX) is a biotechnology company specializing in research, development, and commercialization of novel drugs for the treatment of infectious diseases. The company focuses on the discovery and development of innovative drugs targeting various types of infectious diseases, including fungal infections and resistant bacteria. SCYNEXIS aims to develop drugs that are effective and safe for patients with infectious diseases and can bring improvements in the treatment of these conditions. The company also conducts clinical trials and collaborates with medical institutions and pharmaceutical companies to further develop and commercialize its drugs. SCYNEXIS, Inc. (SCYX) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company with a focus on developing new drugs for the treatment of infectious diseases.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

David Angulo

Employees

18

Headquarters

Jersey City

Upcoming events

04 NOV

Earnings

Upcoming earnings report

44d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.